SaxoCell Conference 2026

SaxoCell Conference 2026
Go back

SaxoCell Conference 2026

From Lab to Life: Advancing Cell and Gene Therapies Together

Join us at the SaxoCell Conference 2026 in Dresden, where leading minds from science,industry, and politics come together to shape the future of safe and accessible cell and genetherapies — bridging innovation and implementation.

The SaxoCell Conference 2026 is your opportunity to engage with experts, innovators, and decision makers in the field of cell and gene therapies. As part of the BMBF Clusters4Future initiative, SaxoCell is one of Germany’s leading centres dedicated to researching new applications and production methods for personalised therapies and ‘living drugs’.

What to Expect:

  • Insights into the latest scientific advancements in cell and gene therapies.
  • Opportunities to network with professionals from academia, industry, and policy.
  • Discussions on how Germany is contributing to the future of Cell and Gene Therapy.

Date: 02 – 03 June 2026
Location: Penck Hotel, Dresden

Whether you’re a scientist, industry leader, or policymaker, the SaxoCell Conference offers a platform to
exchange ideas and collaborate on shaping the future of healthcare.

You can find more information about SaxoCell at www.saxocell.de

Register now to be part of this important event!

https://eveeno.com/saxocell_conference_2026

BioRN members receive a 20 % discount.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

register now

Our latest News

discover more
Providing a cellular ‘all-clear’ signal to resume protein synthesis

Providing a cellular ‘all-clear’ signal to resume protein synthesis

Researchers’ newest technologies allow them to discover tiny protein that plays a big role in awakening dormant cells when it’s safe to resume normal operations Summary It’s a tough world for microbes. When resources grow limited and environments worsen, microbes have figured out ways to hunker down and go dormant until conditions improve. However, scientists […]

read more
Scientists uncover thousands of new proteins in ‘dark proteome’

Scientists uncover thousands of new proteins in ‘dark proteome’

An international consortium has found over 1,700 new proteins from noncoding DNA, many of which show potential as targets for cancer immunotherapy In a collaborative effort, scientists in the TransCODE consortium reveal more than 1,700 new proteins that could have implications for human diseases, including cancer. These tiny proteins were found in what’s called the […]

read more
The Plasticity of Malignant Brain Tumors as a Potential Therapeutic Approach: Sibylle Assmus Prize for Neuro-Oncology Awarded to Moritz Mall

The Plasticity of Malignant Brain Tumors as a Potential Therapeutic Approach: Sibylle Assmus Prize for Neuro-Oncology Awarded to Moritz Mall

The ability of cancer cells to change their identity makes tumors such as glioblastoma particularly aggressive and resistant to treatment. Moritz Mall, of the German Cancer Research Center (DKFZ) and the Hector Institute for Translational Brain Research (HITBR), is investigating how this plasticity can be specifically restricted. His approach focuses on genetic “guardians” that suppress […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp